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Abstract
Background: A crucial step in the metastatic spread of ovarian cancer (OC) is the adhesion and implantation of
tumor cells to the peritoneal mesothelium. In order to study this step in the cascade, we derived a pro-metastatic
human ovarian carcinoma cell line (MFOC3) from the non-metastatic FOC3 line.
Methods: Molecular profiling of the isogeneic lines identified differentially expressed genes, and investigation for a
role in dissemination for specific factors was achieved by development of a co-culture adhesion assay utilizing
monolayers of human mesothelial cells.
Results: After murine intraperitoneal inoculation, the FOC3 cell line formed no metastases, but the MFOC3 subline
formed metastases in > 80% of SCID mice. MFOC3 cells also adhered 2-3 times more avidly to mesothelial
monolayers. This adhesion was inhibited by neutralizing antibodies to IL-1b and enhanced by recombinant IL-1b (p
< 0.01). IL-1b induced mesothelial cell b1-integrin, and an antibody to this subunit also inhibited the adhesion of
MFOC3 to mesothelial cells in vitro and significantly reduced metastases in vivo. Immunohistochemical analysis of a
cohort of 96 ovarian cancer cases showed that negative IL-1b expression was significantly associated with an
improved overall survival rate.
Conclusions: These results suggest that a IL-1b/b1-integrin axis plays a role in ovarian tumor cell adhesion to
mesothelia, a crucial step in ovarian cancer dissemination.
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Background
Ovarian cancer (OC) is the most lethal gynecologic
malignancy in industrialized countries. The overall 5-
year survival rate of ovarian cancer patients is 30% to
50%, largely due to the fact that the majority of these
patients are diagnosed at an advanced stage (III or IV)
of disease at initial diagnosis [1]. Substantial advances in
the treatment of primary OC have occurred, but patient
morbidity and mortality remain high due to metastatic
dissemination [2]. Ovarian tumor cells primarily disse-
minate by shedding into the peritoneal cavity where
they can implant on to the mesothelium that covers the
omentum and bowel surface [3]. In order for the tumor
cells to establish secondary foci and invade the underly-
ing stroma, they need to adhere to and interact with the
peritoneal mesothelial cells. This is a crucial step in OC
progression and is a possible target for chemotherapeu-
tic intervention, yet few studies have focused on this
interaction. Identifying crucial factors involved in the
crosstalk between the tumor cells and the mesothelial
microenvironment will not only improve our under-
standing of the disease but will ultimately enable us to
provide better patient care.
Details of the mechanisms involved in OC cell adher-
ence to mesothelium are unclear, but the dynamics of
this interaction appear to be relatively rapid, in the
order of minutes [4,5]. Potential molecular interactions
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teins such as collagens type I and IV, laminin, and fibro-
nectin via integrins, and binding to hyaluronan
expressed on the surface of human peritoneal mesothe-
lial cells via CD44 [5-7]. The secretion of proteolytic
enzymes, cytokines, and growth factors by both tumor
cells and mesothelium will contribute to the regulation
of adherence, survival and further dissemination. Recent
studies have demonstrated that c-Met overexpression is
a prognostic factor in ovarian cancer and that targeting
c-Met in vivo inhibits peritoneal dissemination and inva-
sion through an a5 b1 integrin-dependent mechanism
[8].
In order to facilitate the study of ovarian tumor cell-
mesothelial cell interactions, in this study we established
a novel human ovarian cancer xenograft model, and a
reproducible OC adherence assay for the investigation
of the interaction and behavior of a highly metastatic
OC cell line (MFOC3). Differential gene expression ana-
lysis was employed to identify genes with potential
mechanistic influence, and one of these, interleukin-
1beta (IL-1b) was found to be pivotal for increased
adherence of the ovarian cell line to human mesothelial
cells. Immunohistochemical evaluation of ovarian tumor
tissues revealed a significant correlation between with
IL-1b expression and overall survival. The derivation of
this ovarian tumor xenograft model provides a powerful
experimental system for the controlled evaluation of
molecular mechanisms involved in ovarian carcinoma
dissemination and metastasis.
Methods
Ovarian cancer cell culture
The human ovarian cancer cell line, FOC3 was kindly
provided by Dr. T. Fukuda (Fukushima Medical Univer-
s i t y ,F u k u s h i m a ,J a p a n )[ 9 ] .O v a r i a nc a n c e r( O C )c e l l
lines were maintained in Dulbecco’s modified Eagle’s
medium (DMEM) in the presence of 10% fetal bovine
serum (FBS) and 50 U penicillin-streptomycin at 37°C
in a humidified atmosphere of 5% CO2.
Establishment of an intraperitoneal human ovarian cancer
xenograft model
Exponentially growing cells were harvested with trypsin-
EDTA, washed and resuspended in FBS-free DMEM.
For subcutaneous (s.q.) inoculation, 1 × 10
7 FOC3 cells
in 0.2 ml of DMEM/50% Matrigel (BD Bioscience, San
Jose, CA) were injected s.q. into the left inguinal region
of 6 week-old female severe combined immunodefi-
ciency (SCID) female mice (Nihon Clea, Tokyo, Japan).
FOC3 and MFOC3 cells were injected into 10 and 16
animals respectively. When the primary xenograft tumor
reached a diameter of 1 cm, the tumor was removed,
and minced with scissors aseptically, and seeded into a
petri dish. After several passages, the surviving culture
was designated MFOC3. A total of 1 × 10
7 FOC3 and
MFOC3 cells in 0.5 ml PBS were injected intraperitone-
ally (i.p.) into SCID female mice. All mice were sacri-
ficed 13 weeks after the injection and visible tumor,
mesenterium, peritoneum, omentum and diaphragm
were removed, fixed in 20% buffered formalin and pro-
cessed for hematoxylin and eosin (H&E) staining. Fre-
quency of peritoneal metastasis between FOC3 and
M F O C 3w e r ec o m p a r e db yt h ec2 test (StatView, SAS
Institute, Cary, NC, USA). p < 0.05 was considered to
be statistically significant. This experiment was approved
by the Institutional Animal Care and Use Committee of
Fukushima Medical University (Ref# KO3129).
Primary culture of Mesothelial cells
Human mesothelial cells (MCs) were isolated from the
peritoneum of patients who were undergoing surgery
for benign conditions at Fukushima Medical University
School of Medicine and Tsuboi hospital. Written
informed consent was obtained from all patients as per
IRB approval from the Fukushima Medical University
School of Medicine, and all documentation is retained
within patient files. The procedure was based on techni-
ques described in previous articles
7,9-15.B r i e f l y ,M C s
were collected by scrubbing the peritoneum with a cold
knife. The MCs were cultured using DMEM contained
10% FBS and 50 U penicillin-streptomycin at 37°C in a
humidified atmosphere of 5% CO2. The MC’s were used
in experiments at passage 2-5.
Microarray analysis
Difference mRNA transcript expression between FOC3
and MFOC3 was investigated using the Human Cancer
CHIP microarray, version 2.1 (Takara, Shiga, Japan)
containing probes to 557 human genes reportedly asso-
ciated with cancer. Total RNA was isolated from culture
cells using TRIZOL (GIBCO, Grand Island, NY), and
mRNA was further purified using an oligotexTM-dT30
‘Super-mRNA Purification kit’ (Takara). cDNA labeled
with Cy3-dUTP or Cy5-dUTP was generated from 1 ug
of FOC3 and MFOC3 mRNA using Takara RNA Fluor-
escence Labeling Core Kit (Takara), and 50 pg of
lambda A was labeled as an internal control. Cy3 and
Cy5-labeled probe were co-hybridized to the microar-
rays in hybridization solution (6 × SSC, 0.2% SDS, 5 ×
Denhardt’s solution, carrier DNA) at 65°C over night,
and the microarray slide processed as previously
described (Nagata, et al, 2003). The Cy3 and Cy5 fluor-
escence intensities were captured with a 428 array scan-
ner (Affymetrix, Santa Clara, CA) with separate
measurement of the sample intensities for Cy3 and Cy5.
The intensity of each hybridization signal was evaluated
photometrically using Imagene software (BioDiscovery,
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nal of a housekeeping gene, GAPDH. The Cy3/Cy5 ratio
for each sample was calculated by averaging the spots,
and the cutoff value for each expression level was calcu-
lated according to the background noise. For this cutoff,
we used an expression level of above 100 where the
fluctuation was less than a critical value (1.0) because
other genes (those with low expression) are embedded
in the background noise. Upregulated and downregu-
lated genes in the MFOC3 cells were defined as those
having a Cy3/Cy5 signal ratio of > 3.0 and < 0.50,
respectively.
RT-PCR
We confirmed the differential expression of the IL-1b
gene using RT-PCR. 2 ug of total RNA was reverse-
transcribed using a first strand cDNA synthesis kit (Invi-
trogen, Carlsbad, CA). 1 μlo ft h ef i r s ts t r a n dc D N A
preparation was added to the PCR reaction. The primers
for IL-1b were as described by McAlindon et. al. [10].
Oligonucleotide IL-1b primers; 5’ATGGCAGAAG-
TACCTAAGCTCGC-3’ and 5’-TTGACTGAAGTGG-
TACGTTAAACACA-3’ (PCR product 802 bp). GAPDH
primers; 5’-GCACAGTCAAGGCAGAGAGAAC-3’ and
5’-CTTATGACCACTGTCCACGC-3’ (PCR product 420
bp). PCR was performed using TAKARA™ Ex Taq
(Takara). PCR for IL-1b was performed with 30 cycle of
denaturation for 30 seconds at 94°C, annealing for 30
seconds at 62°C, and elongation for 1 minute at 72°C.
PCR for GAPDH was performed with 20 cycle of dena-
turation for 30 seconds at 94°C, annealing for 30 sec-
onds at 56°C, and elongation for 1 min at 72°C. PCR
products were electropohoresed on a 1.5% agarose gel
and visualized using ethidium bromide staining.
Western blot analysis
In order to confirm the differential expression of IL-1 b
in the cell lines, we performed Western blot analysis.
Freshly cultured OC cells were lysed in a CellLytic™-
M Tr e a g e n t( S i g m a ,S t .L o u i s ,M O ) ,a n dp r o t e i nc o n -
centration of lysates were quantified by the Bradford
method using Bio-Rad protein assay (Bio-Rad, Hercules,
CA). Cell lysates (20 ug) were electrophoresed on BIO-
RAD ready gels 4-20% Tris-HCL (Bio-Rad) and electri-
cally transferred to a PDVF membrane (Bio-Rad). The
membrane was blocked with 1xTBS, 5% nonfat dry
milk, 0.05% Tween20 and incubated overnight at 4°C
with 2 ug/ml mouse anti-human IL-1b antibody (R&D
Systems, Abinghdon, UK), and 1 hr at room tempera-
ture with 1:2000 dilution of anti-mouse IgG conjugated
HRP (Amersham Pharmacia Biotech, Tokyo, Japan). As
a loading control, horseradish peroxidase-conjugated
polyclonal antibody to b-actin (1:2000) (Santa Cruz,
Santa Cruz, CA) was applied as described for primary
antibodies above. Immunoreactive bands were visualized
using ECL Western blot detection system (Amersham
Pharmacia Biotech) following manufacturer’s protocol.
GFP transfection of OC cell lines
Transfection was performed using SuperFect
® Transfec-
tion Reagent (Qiagen, Tokyo, Japan) according to the
manufacture’s protocol, with minor modification. Briefly,
2×1 0
5 of OC cells were placed in a 35 mm dish the
day prior to transfection. 2 ug of the pEGFP-N1 plasmid
(Clontech, Palo Alto, CA) was mixed with 12 μlo f
SuperFect
® reagent per dish in serum-free DMEM (final
volume of 60 μl), and DNA-lipid complexes were
formed by incubation for 10 min at room temperature.
DNA-lipid complex was incubated with FOC3 and
MFOC3 cells for 3 hours, cells were washed with PBS,
and 2 ml DMEM with 10% FBS was added. Three days
later, the cells were exposed to 500 ug/ml G418. The
limiting dilution method was used with medium con-
taining G418 (500 ug/ml; Promega, Madison, WI) for
generation of monoclonal cell lines. Single, GFP-positive
cells in 96-well plates were detected using fluorescence
microscopy (Olympus, Tokyo, Japan). To confirm the
tumorigenicity of GFP labeled cells, these derivative
lines were inoculated into SCID mice (as described
above). In the absence of any co-inoculated cytokines,
GFP labeled FOC3 (0/10 animals) and MFOC3 (8/10
animals) had very similar propensity to the unlabeled
cell lines with respect to peritoneal tumorigenesis.
In vitro adhesion assay
In order to compare the difference between FOC3 and
MFOC3 adhesion to mesothelial cells (MCs), 1 × 10
5
GFP labeled FOC3 and MFOC3 cells in serum free
DMEM were placed over mesothelial monolayers in an
uncoated 24-well plate and incubated at 37°C for various
periods. Students’s t-test was performed as a test of sig-
nificance (StatView, SAS Institute, Cary, NC). Data was
presented as mean ± SD. p < 0.05 was considered to be
statistically significant.
The effect of recombinant IL-1b on OC adhesion to
mesothelium was achieved by adding different concen-
trations of recombinant IL-1b (R&D) in serum free
DMEM incubated at 37°C for 30 minutes. To observe
inhibition of IL-1b and integrin b1 on OC cell adhesion,
1×1 0
5 FOC3-GFP, MFOC3-GFP and FOC3-GFP con-
taining 20 ng/ml recombinant IL-1b and neutralizing
antibodies of IL-1b and b1 integrin (Chemicon, Teme-
cula, CA) in serum free DMEM were placed over
mesothelial monolayers in an uncoated 24-well plate
and incubated at 37°C for 60 minutes. Normal mouse
IgG (Amersham Pharmacia Biotech) was used as a nega-
tive control. Both antibodies were used at 10 ug/ml,
since preliminary experiments demonstrated that this
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binding to mesothelium. For all assessments, nonadher-
ent cells were removed by washing twice with PBS after
incubation. The adherent cells were fixed by 4% parafor-
maldehyde and counted at 100x under a fluorescence
microscope. These data were analyzed by one-way ana-
lysis of variance with the Bonferroni/Dunn test (Stat-
View). Data was presented as mean ± SD. P <0 . 0 5w a s
considered to be statistically significant.
In Vivo Assessment of Ovarian Cancer Peritoneal
Metastasis
To determine the effect of IL-1b and integrin b1a n t i -
body on ovarian cancer peritoneal metastasis in vivo,1
×1 0
7 MFOC3 cells with anti-IL-1b (10 ug/ml) and anti-
b1 integrin (10 ug/ml) in 0.5 ml PBS were injected i.p.
into SCID female mouse. Normal mouse IgG (10 ug/ml)
was used as a negative control. All mice were sacrificed
after 13 weeks, and tumors visible on the mesenterium,
peritoneum and diaphragm were monitored under low-
power magnification. Frequency of peritoneal metastasis
between MFOC3 and MFOC3 with anti IL-1b or anti
b1 integrin were compared by the c2 test (StatView). p
< 0.05 was considered to be statistically significant.
Flow cytometry
Analysis of adhesion molecules in MCs was detected
using Flow cytometry. At confluency, MCs were washed
twice with fresh culture media and then incubated with
20 ng/ml recombinant IL-1b in serum free RPMI 1640
for 30 minutes. MCs were harvested using trypsin
(0.05%) and EDTA (0.02%) and resuspended in PBS
with 2% FBS. 100,000 cells treated with primary mono-
clonal antibodies for integrin a1 (Chemicon), integrin
a2 (SouthernBiotec, Birmingham, AL), integrin a5
(Cymbus Biotechnology, Hampshire), integrin a6( C h e -
micon), integrin aV (Chemicon) and CD44 (Southern-
Biotec) at a dilution of 1:15, and integrin b1 (Chemicon)
at a dilution 1:100, at 4°C for 30 minutes. Cells were
washed twice in PBS with 2% FBS, and labeled with
FITC-conjugated rabbit-anti-mouse Ig (Dako, Tokyo,
Japan) at 4°C for 30 minutes. After two additional
washes, the cells were analyzed using a flow cytometry
(BD Bioscience, San Jose, CA). Statistical analysis was
performed using the Students’s t-test for paired data
(StatView). Fluorescence intensities are presented as
median ± SD absolute deviation in relation to control,
which were set as 100%. p < 0.05 was considered to be
statistically significant.
Patient Population
Patients with a diagnosis of early stage (stages I and II)
ovarian carcinoma were identified at Fukushima Medical
University School of Medicine and Tsuboi hospital
during a 10 year period from 1995 to 2004. The clinical
stage was determined using FIGO criteria. A total of 96
patients had primary surgical cytoreductive surgery with
no exposure to prior chemotherapy. The median age of
the patients was 50.7 years (range 12-86). All patients
gave informed consent before their inclusion in this
study. Association between IL-1b expression and age,
histology and ascites were assessed using c2t e s t( S t a t -
View). p < 0.05 was considered to be statistically
significant.
Immunohistochemistry
Paraffin-embedded tissue sections were deparaffinized,
and endogenous peroxidases were inactivated by a 15-
min treatment with methanol containing 3% hydrogen
peroxide. Sections were subjected to heat-induced anti-
gen retrieval for 15 min at 100°C in 10 mM citrate buf-
fer before addition of the primary antibody. After
nonspecific binding was blocked with goat serum for 30
min, all slides were incubated overnight at 4°C for over-
night with a 1:50 dilution of rabbit antihuman IL-1b
antibody (Santa Cruz Biotechnology, Santa Cruz, CA).
After incubation, an avidin-biotin-peroxidase reaction
was performed using Histofine SAB-PO(R) kit (Nichirei,
Tokyo, Japan) following manufacturer’sp r o t o c o l .T h e
sections were subjected to diaminobenzidine for 10 min
and counterstained with Mayer’s hematoxylin.
IL-1b expression was estimated in a combined scoring
system based on both the percentage of positive cells
(negative = 0, < 10% = 1, 11-50% = 2, and 51-80% = 3,
> 81% = 4) and the staining intensity (negative = 0,
weak = 1, moderate = 2, and strong = 3). The final
immunoreaction score (IRS) was obtained by multiplica-
tion of the % value of positive cells by the value for
staining intensity. The IRS can range from 0 to 12, and
the cases of 4 to 12 and 0 to 3 were defined as high and
low expression of IL-1b respectively. Survival curves
were calculated using the Kaplan-Meier method, and
differences in survival were analyzed using the log-rank
test (SPSS 12.0, SPSS Co., Tokyo, Japan). In all analyses,
statistical significance was defined as a probability value
less than 0.05.
Results
Selection of FOC3 cells with a high propensity for
peritoneal metastasis
The human ovarian cancer cell line FOC3 was estab-
lished from a human ovarian serous cystadenocarcinoma
[9]. FOC3 does not exhibit metastatic potential when
introduced into athymic mice by intraperitoneal implan-
tation. As shown in other xenograft models, prolonged
growth of a cancer cell line in a murine host can adapt,
or select cells for more robust growth in the same host
in a subsequent inoculation. In order to derive a more
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7
cells into the inguinal region of female SCID mice, the
xenograft was recovered, disaggregated and cultured for
several passages. Proliferation of the FOC3 and MFOC3
cell lines did not differ significantly in tissue culture.
This sub-population, designated MFOC3, and the paren-
tal FOC3 population were injected intraperitoneally into
SCID under the same conditions. At 13 weeks, FOC3
tumors were not discovered in any of ten mice. Conver-
sely, peritoneal tumors were evident in 13 of 16 mice
(81.3%) inoculated with MFOC3 cells (Table 1A).
MFOC3 tumors were observed on the mesenterium,
peritoneum, omentum, and diaphragm (Figures 1A and
1B). FOC3 cells form a monolayer sheet of polygonal
cells with pavement-like arrangement in culture. In cul-
ture, no major distinct morphological differences
between the parental FOC3 and the malignant MFOC3
cells were observed.
Differentially gene expression associated with peritoneal
metastasis
Gene expression profiles of FOC3 and MFOC3 cells
were compared in order to identify genes that may be
associated with the metastatic or non-metastatic cellular
phenotype. mRNA samples were profiled using the
Human Cancer CHIP microarray, which contains 557
human cancer-related genes.
The analysis revealed 41 up-regulated genes (> 3-fold
change), and 37 down-regulated genes (< 0.50-fold
change) in MFOC3 cells. Selected genes are listed in
Table 2 and the full lists of differentially expressed
genes are available on request. Genes up-regulated in
MFOC3 included cell adhesion molecules (ADAM9,
ITGA8, CTNNΒ1), proteolytic enzymes (PAI2), cyto-
kines (IL1b, TNF), growth factors (FGF1, NRG,
TGFΒ1) and apoptosis inhibitors (API1, API2). The
expression level of PAI2 in MFOC3 was 25 times
higher than that of FOC3. Genes in the keratin cytos-
keleton family (KRT19, KRT14, KRT18 and KRT13)
were consistently decreased in MFOC3. The expression
level of KRT19 was 10 times lower in MFOC3 than in
FOC3. Decreased expression of cell adhesion molecules
(ITGB8, ITGA9), caspase 1 and an inhibitor of metas-
tasis (NME1) were also observed in MFOC3 cells. The
increased expression of interleukin-1beta (IL-1b)i n
metastatic MFOC3 cells was of particular interest to us
because it has previously been implicated in cancer cell
dissemination [11]. To validate the microarray profile
result, we monitored the comparative levels of IL-1b
using RT-PCR analysis. IL-1b mRNA transcript levels
were confirmed to be significantly higher in MFOC3
cells (Figure 2A). The differential expression of IL-1b
protein was confirmed to follow the same pattern
using Western blot analysis (Figure 2B).
Cell adhesion is influenced by tumor cell IL-1b and
mesothelial cell b1 integrin
A reproducible assay was designed to test the adhesion
of FOC3 and MFOC3 cells to human mesothelial cells
(MCs). MCs were maintained in culture as a monolayer
for 2-5 passages. GFP labeled FOC3 and MFOC3 cells
were allowed to bind to the MCs for 10 min, 20 min, 30
min and 60 min. Adherent cells remaining after washing
were counted. Adhesion of OCs increased with time
(Figure 2C). MFOC3 cells adhered more readily to MCs
than FOC3. The increased adherence rate observed was
in the order of 2-3 times greater, and remained constant
up to 30 minutes (Figure 2C). For all subsequent adhe-
sion assays, the 30 min time point was used.
Preincubation of MCs with recombinant IL-1b caused
a significant increase in FOC3 adhesion to (Figure 3A).
This effect was dose-dependent. Significant stimulation
was already achieved at 10 ng/ml, and maximum stimu-
lation was achieved with the addition of 20 ng/ml IL-1b
(p < 0.01) in the adhesion assay. The augmented adhe-
sion at this concentration was at least double that of
adhesion achieved in the absence of recombinant IL-1b.
Furthermore, inclusion of a neutralizing IL-1b antibody
in the assay significantly decreased MFOC3 adhesion to
MCs in a concentration-dependent manner (Figure 3B),
with maximal inhibition at ~65% of control using 10
μg/ml antibody. These findings indicate that IL-1b plays
a pivotal role in the adhesion of FOC3 cells to MCs. To
investigate the specific effect of IL-1b on MCs, we per-
formed flow cytometry to monitor the expression of a
panel of cell adhesion molecules. Treatment of MCs
with IL-1b ( 2 0n g / m lf o r3 0m i n u t e s )r e s u l t e di nas i g -
nificant increase in the expression of b1 integrin (Figure
4A). The median level of b1 integrin was increased by
21.5% (P < 0.01) in the presence of IL1b. Treatment of
MCs with IL-1b had no significant effect on the
Table 1 Peritoneal Metastasis and Inhibition
A) Peritoneal metastasis after intraperitoneal transplantation of
FOC3 and MFOC3
Cell Line Number of Mice Number of Mice with Metastasis (%)
FOC3 10 0(0)
MFOC3 16 13 (81.3) *
*FOC3 vs MFOC3: p < 0.01 (c2 test)
B) Inhibition of Peritoneal metastasis in MFOC3 cells by anti-IL-1b
and anti- integrin b1
Antibody Number of Mice Number of Mice with Metastasis (%)
control 10 8 (80) a
IL-1b 10 7 (70) b
Integrin b1 10 2 (20) c
a vs b: non significant;
a vs c: p < 0.01 (c2 test)
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Figure 1 Representative appearance of intraperitoneal (i.p.) tumor implants in SCID mice. A. Macroscopic view of a peritoneal metastatic
tumor after i.p. injection of MFOC3. Small round metastatic foci of extensive local growth (arrowhead) are present in the peritoneum, omentum
and mesenterium. B. Microscopic view of a peritoneal metastatic tumor after i.p. injection of MFOC3. MFOC3 cells (arrowhead) grew on the
peritoneum.
Table 2 Selected genes shown to be differentially expressed between Foc3 and MFOC3 cells by transcriptomic
profiling.
Downregulated in MFOC3
Gene Symbol Gene Name Fold Change Function
KRT19 Keratin 19 0.10 cytoskeleton
KRT14 Keratin 14 0.13 cytoskeleton
ITGB8 Integrin beta 8 0.19 cell and matrix adhesion
KRT13 Keratin 18 0.24 cytoskeleton
KRT18 Keratin 13 0.30 cytoskeleton
CASP1 Caspase 1 0.33 IL1beta convertase
ITGA9 Integrin alpha 9 0.39 cell and matrix adhesion
ESR1 Estrogen receptor 1 0.41 hormone receptor
NME1 Non-metastatic protein 1 0.49 inhibitor of metastasis
Upregulated in MFOC3
Gene Symbol Gene Name Fold Change Function
PAI2 Plasminogen activator inhibitor type II 25.56 proteolytic enzyme
IL1B Interleukin 1beta 11.11 cytokine
TNF Tumor necrosis factor 7.88 cytokine
API2 Apoptosis inhibitor 2 7.44 inhibition of apoptosis
TGFB1 Transforming growth factor 5.30 cell adhesion regulation
PLAU Plasminogen activator, urokinase 4.50 proteolytic enzyme
FGFR1 Fibroblast factor receptor 1 4.34 growth factor receptor
API1 Apoptosis inhibitor 1 4.26 inhibition of apoptosis
ITGA8 Integrin alpha 8 3.95 cell and matrix adhesion
LAMB1 Laminin, beta1 3.88 extracellular matrix
FGF1 Fibroblast growth factor 1 3.79 growth factor
SDC1 Syndecan 1 3.19 membrane protein
CTNNB1 Catenin, beta1 3.03 cell adhesion
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(Figure 4A).
Inclusion of a neutralizing anti-b1 integrin antibody in
the adhesion assay significantly inhibited MFOC3 cell
adhesion to MCs in a dose-dependent fashion. Reduc-
tion of adhesion to approximately 60% of control was
observed at 10 and 100 μg/ml (Figure 4B). Figure 3C
depicts a graphical summary of the effects of recombi-
nant IL-1b,a n t i - I L - 1 b antibody and anti-b1i n t e g r i n
antibody on FOC3 and MFOC3 cell adhesion. The
adhesion of MFOC3 to MCs was greater than that of
FOC3, however, the adhesiveness of FOC3 to MCs was
increased to a level similar to that of MFOC3 by recom-
binant IL-1b (Figure 4C). The adhesion of both MFOC3
and FOC3 cells to MCs were inhibited by treatment
with neutralizing anti- IL-1b and anti-b1 integrin anti-
bodies to an equivalent extent, but the two antibodies
did not have a synergistic effect. Through immuno-
chemical staining and flow cytometry the well-character-
ized b1 integrin ligands fibronectin and laminin were
found to be present equally in FOC3 and MFOC3 cells
(data not shown).
Effect of IL-1b in a murine metastasis model
To determine the effect of IL-1b and b1 integrin antibo-
dies on ovarian cancer peritoneal metastasis in vivo,1×
10
7 MFOC3 cells with anti-IL-1b (10 ug/ml) and anti-
b1 integrin (10 ug/ml) were administered together in 0.5
ml PBS were injected i.p. into SCID female mouse. Nor-
m a lm o u s eI g G( 1 0u g / m l )w a su s e da san e g a t i v ec o n -
trol. Peritoneal metastasis resulting from i.p. inoculation
of MFOC3 was observed in 8 of 10 mice (80%) (Table
1B). MFOC3 metastases were also observed in 7 of 10
(70%) mice treated with anti IL-1b. In contrast, MFOC3
produced peritoneal metastasis in only 2 of 10 (20%)
mice when mice were treated with anti b1 integrin anti-
bodies (Table 2). Treatment with anti-b1i n t e g r i n
resulted in a significant decrease (p < 0.01) in the num-
ber of mice with metastases compared to control.
Relationship between IL-1b expression and prognosis in
early-stage ovarian cancer patients
We investigated the expression of IL-1b in archival tis-
sues obtained from 96 early-stage ovarian cancer cases.
The histological summary of the cases is described in
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Figure 2 Validation of IL-1b expression and cell adhesion assay. A. RT-PCR analysis of IL-1beta was performed on FOC3 and MFOC3 mRNA
using GAPDH as the internal control. B. Expression of IL-1b protein. Western blot analysis was performed on FOC3 and MFOC3 cell samples with
anti- IL-1b, using b-actin as the loading control. C. Tumor cell adhesion assay. GFP-labeled FOC3 (▲) and MFOC3 (●) cells were added to the
confluent mesothelial cell monolayer for 10, 20, 30 and 60 minutes and counted using fluorescent microscopy after washing away unattached
cells. Each point represents the mean ± SD of at least three times separate experiments. * p < 0.05, ** p < 0.01.
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Page 7 of 13Table 3; serous (25 of 96; 26.0%), mucinous (24 of 96;
25.0%), endometrioid (26 of 96; 27%), and clear cell (21
of 96; 21.9%). Immunohistochemical analyses revealed
that many cases of OC were positive for IL-1b expres-
sion (Figures 5A,B). Expression of IL-1b was scored as
high or positive (IRS score 4-12) and low or negative
(IRS score 0-3). High expression of IL-1b was rated as
20.0% in serous, 37.5% in mucinous, 30.7% in endome-
trioid, and 42.8% in clear cell cases (Supplemental S1).
High expression of IL-1b was observed in 32.3% (31/96)
of all early-stage OCs examined. There was no signifi-
cant association between histological type and IL-1b
expression (p = 0.372), although the IL-1b high expres-
sion rate in clear and mucinous tumors was greater
than that observed in serous and endometrioid tumors.
Patients older than 50 years, and patients with ascites
were more likely to be positive for IL-1b (37.2 versus
26.7% and 36.7 versus 28.8 respectively), but this did
not reach statistical significance. Kaplan Meier survival
plots of overall survival revealed that 9 of 31 (29%)
patients whose tumors expressed IL-1b died from dis-
ease (most often from peritoneal metastases) within the
follow-up period (5 years), compared to only 1 of 65
(1.6%) patients whose tumors did not express IL-1b
(Figure 5C). IL-1b expression was significantly asso-
ciated with overall survival in early-stage OC cases (p =
0.034).
Discussion
Despite improvements in surgery and treatment of ovar-
ian cancer, the long-term survival of patients with this
disease is limited due to the intraperitoneal (i.p.) spread
of tumor cells from the primary tumor mass. A crucial
step in the establishment of secondary foci is the adher-
ence of disseminated tumor cells to the mesothelial sur-
faces of the peritoneum. Thus, a potentially efficacious
adjuvant therapy approach could involve the i.p. admin-
istration of agents that target tumor cell and mesothelial
cell interactions. To better understand the pivotal pro-
cesses, we developed an in vitro cell adhesion model in
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Figure 3 A. FOC3 cell adhesion to mesothelial cells after pre-incubation with 1, 10, 20 or 100 ng/ml recombinant IL-1b. * p < 0.01 B.
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Page 8 of 13order to identify key molecules and to test their effect
on phenotype. Findings from the model were subse-
quently confirmed in human tissue specimens.
By ‘conditioning’ FOC3 cells through immune-com-
promised mice [12,13] we derived the MFOC3 sub-line
by recovery from an advanced FOC3 xenograft tumor
formed in SCID mice. Unlike FOC3 cells, inoculation of
the MFOC3 subline resulted in multiple tumors across
the peritoneal cavity in multiple experiments. These iso-
geneic cell line populations constitute a valuable model
for the elucidation of mechanisms involved in peritoneal
metastasis of ovarian cancer cells. It is to be noted that
our molecular profiling was restricted to 557 genes and
so cannot be considered comprehensive, but of particu-
lar interest from our differential gene expression ana-
lyses was the confirmed increased expression of
interleukin-1beta (IL-1b) in metastatic MFOC3 cells. IL-
1b has previously been implicated in peritoneal
mesothelium integrity [14] and in cancer cell dissemina-
tion [11,15]. Development of an in vitro cell adhesion
assay using human mesothelial cells (MCs) enabled the
testing of a role for IL-1b in OC/MC cell adhesion. Pre-
vious studies, have performed similar in vitro adhesion
assays using isolated human mesothelial cells [16,17],
but here we monitored intact adherent cells accurately
by tracking GFP-labeled FOC3 and MFOC3 cells. In
these assays, MFOC3 cells were observed to adhere up
to 3 times more avidly than the parental FOC3 cell
population, and a dose-dependent increase in FOC3
adhesion after preincubation of MCs with IL-1b was
observed. The specificity of this effect was confirmed by
neutralization with an IL-1b antibody and reduction of
MFOC3 adhesion to MCs in a dose-dependent manner.
These findings indicate that IL-1b plays a pivotal role in
the adhesion of FOC3 cells to MCs. A role for IL-1b in
cell adhesion has been reported in different model sys-
tems. For example, IL-1b promoted the adherence of
human colorectal carcinoma cell lines and melanoma
cell lines to endothelial cells in a dose-dependent man-
ner [18,19].
To monitor the effects of IL-1b treatment on MCs we
measured the expression of a panel of adhesion mole-
cules. No differences were observed in the MC expres-
sion of CD44, or 5 of 6 integrins monitored by flow
cytometry, but an increase in the expression of MC b1
integrin was evident. Inclusion of a neutralizing anti- b1
integrin antibody in our in vitro cell adhesion assay sig-
nificantly inhibited MFOC3 cell adhesion to MCs in a
dose-dependent fashion. In combination, these analyses
show that the increased adhesion of MFOC3 to MCs is
influenced by the release of IL-1b released from the
Figure 4 A. Expression of cell adhesion molecules on
mesothelial cells (MCs). MCs were exposed to IL-1b (20 ng/ml) for
30 minutes, and expression of a panel of adhesion molecules was
assessed by flow cytometry. Untreated control was set as 100%.
Results are presented as median values ± median absolute
deviation in relation to control. Data are representative of five
experiments. * p < 0.01. B. Inhibition of MFOC3 adhesion to
mesothelial cells by 1, 10 or 100 ug/ml anti-b1 integrin * p < 0.05.
Control (C) experiment was performed in the presence of 100 ug/
ml mouse IgG. C. Summary of the effects of anti-IL-1b (10 ug/ml)
and b1 integrin (10 ug/ml) on the binding to mesothelial cells of
FOC3 and MFOC3, and FOC3 with recombinant IL-1b (20 ng/ml).
Open bars represent FOC3; shaded bars, MFOC3; solid bars, FOC3
with recombinant IL-1b. Data are expressed as the mean ± SD of
three separate experiments.
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Page 9 of 13Table 3 Association of IL-1b expression and clinicopathological variables
Number of patients IL-1b high expression (%) IL-1b low expression (%) P- value (c2 test)
Ovarian cancer (stage 1+2) 96 31 (32.2) 65 (67.8)
Age (years)
< 50 45 12 (26.7) 31 (73.2)
> 51 51 19 (37.2) 34 (62.8) 0.471
Histological type
Serous 25 5 (20.0) 20 (80)
Mucinous 24 9 (37.5) 15 (62.5)
Endometroid 26 8 (30.7) 18 (69.3)
Clear cell 21 9 (42.8) 12 (57.1) 0.372
Ascites
Negative 52 15 (28.8) 37 (71.2)
Positive 54 16 (36.7) 28 (63.2) 0.432
log-rank : p=0.034 
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induction of cell surface b1 integrin on MCs. The inter-
ference of tumor cell adhesion with neutralizing antibo-
dies was also tested in vivo. MFOC3 metastasis rates of
~80% were not significantly changed in mice treated
with anti- IL-1b antibodies, explained by high rates of
antibody clearance or stability in vivo, or sequestration
of antibodies by murine cytokines or other factors, how-
ever, peritoneal metastasis was observed in only 20% of
mice when treated with anti- b1 integrin antibodies.
Coupled with the presence of ligands laminin and fibro-
nectin on FOC3 and MFOC3 cells, this confirms a role
for the b1 integrin subunit in MFOC3 metastasis to the
peritoneal cavity.
In order to link the model findings to events in
human disease, we investigated the expression of IL-1b
in archival tumor tissues obtained from a cohort of 96
early-stage ovarian cancer cases. Immunohistochemical
analyses revealed no significant association between his-
tological type and IL-1b expression level, but the IL-1b
expression rate was greater in clear and mucinous
tumors than that observed in serous and endometrioid
tumors, and patients with ascites were more likely to be
positive for IL1b. Most importantly, overall survival ana-
lysis revealed that 29% of patients whose tumors
expressed IL-1b died from the disease within a 5-year
follow-up period. In contrast, only 1.6% of patients
whose tumors did not express IL-1b died within this
same period. These results suggest IL-1b might be asso-
ciated with tumors of a more aggressive phenotype, and
interference with its production or action may be a pro-
mising target for ovarian cancer therapy.
A number of studies have focused on identifying tar-
gets that may prove clinically useful in the management
of ovarian cancer patients. Targets under development
include TRAIL, BCL-2 family, EGFR and VEGF, and
clinical trials evaluating agents that inhibit VEGF and
EGFR signaling pathways in ovarian cancer have been
performed [20,21]. Interestingly, there is a link between
IL1b and VEGF. IL-1b triggers the release of pre-exist-
ing, sequestered VEGF from the extracellular matrix,
that then homes to the endothelial compartment where
it induces endothelial cell proliferation [11]. So IL-1b is
upstream of VEGF in the angiogenic pathway and there-
fore plays a key role in the expansion of the vascular
compartment during tumor progression. VEGF actions
in enhancing ovarian tumor metastasis are also thought
to be mediated through crosstalk with integrin cell
adhesion receptors [22]. Previous reports have shown a
role for b1 integrin in the adhesion of OCs to mesothe-
lia, but the hypothesis tested has invariably been that it
is the integrins on the OC cell surface that mediate the
interaction with mesothelial cells [5,15]. Our study
shows that IL-1b released from the tumor cells induces
b1 integrins on the MCs and that axis mediates cell
adhesion between the two cell types. Thus, the IL-1b/
integrin axis may not only advance initial cell adhesion
of ovarian tumor cells to the peritoneum, but trigger a
cascade of events that favor the establishment of dis-
persed secondary tumors. Perturbation of this axis at
any stage of disease may have significant benefit.
The peritoneal mesothelium is a highly specialized
layer of epithelial cells that covers the entire surface of
the abdominal cavity. It serves as a protective anatomi-
cal barrier, and as a low friction, non-adhesive interface
allowing the movement of abdominal organs. Cytokines
present in inflammatory or malignant peritoneal effu-
sions may significantly affect the function and the struc-
ture of the peritoneal mesothelial cell lining [23]. The
cytokine milieu can induce an ‘activated’ mesothelium
which, in turn, results in the secretion of a variety of
factors, including IL-6, IL-8, VEGF [24,25], and IL-1b
[26,27]. In the case where the tumor cell secretes its
own IL-1b, then the phenomenon can occur without
injury, or in an enhanced way at sites already under-
going remodeling.
It is likely that IL-1B plays multiple roles in progres-
sion and/or metastasis in ovarian cancer. It has been
demonstrated that IL-1b can cause major morphological
changes and loss of mesothelium integrity, characterized
by cellular retraction and wide-spread exposure of the
submesothelial ECM [14]. The disruption of the
mesothelial barrier may be important for the progres-
sion of neoplastic disease [28]. Once ovarian carcinoma
cells present in the peritoneal fluid adhere to mesothe-
lial cells, the cancer cells may migrate through this
layer, invade the local organs, and spread to distant
sites. This idea is supported by an in vivo model study
in which damage to the mesothelium caused by a pneu-
moperitoneum resulted in peritoneal tumor spread and
a significant decrease in animal survival [29]. Other
groups have studied the effect of peritoneal wounding
on tumor cell adhesion. The adhesion of CC531, Caco2
and HT29 colon carcinoma cell lines to an autologous
monolayer of rat mesothelial cells [30,31] pre-incubated
with factors released after surgical trauma (IL-1b and
EGF) resulted in at least 60% more cell adhesion in a
dose-dependent manner. Additional blocking experi-
ments with anti-IL-1b resulted in significant inhibition
of the tumor cell adhesion in the model, but they did
not test the effect in vivo. Both IL-1b and TNF has been
shown to regulate ovarian cancer in nude mouse xeno-
graft models [32]. Intraperitoneal recombinant IL-1b
administration led to a dose dependent replacement of
peritoneal ascitic tumour with solid tumours attached to
the peritoneum, and high doses had an anti-tumor
effect. Recombinant human TNF also promoted tumor
implantation in the same xenograft models, but had no
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association between inherited polymorphisms in the IL-
1b gene and various cancers, including cervical, bladder
and breast, but the results remain ambiguous [33,34].
Thus, anti- IL-1b therapy may act on several levels;
reduce tumor cell adhesion, maintain peritoneal integ-
rity, and ameliorate peritoneal tumor cell induced
inflammatory responses that may exacerbate adhesion
and establishment of secondary tumors. Furthermore,
because the frequency of IL-1b expression in human
ovarian cancer specimens was strongly associated with
overall survival, it is possible that IL-1b may also serve
as a biomarker for prognosis or as a monitoring biomar-
ker for therapeutic response. Additional tumor samples
need to be evaluated to investigate the value of IL-1b as
a biomarker with clinical utility.
Conclusions
Cancers originating from organs in the peritoneal cavity
(e.g., ovarian, pancreatic, colorectal, gastric and hepatic)
present treatment difficulties precisely because of the
occurrence of peritoneal metastases. A logical treatment
option is intraperitoneal therapy after surgical removal of
the primary tumor. The clinical utility of this approach
has been hampered by toxicity issues, in part due to the
lack of products designed specifically for intraperitoneal
therapy. Targeted immunotherapy with monoclonal anti-
bodies (mAbs) is a promising strategy in this context. A
mAb could selectively target tumor cells or the mesothe-
lium if we can identify those targets that are biologically
essential to peritoneal dissemination. Therapeutic mAbs
against vascular endothelial growth factor (VEGF) or its
receptor, and human epidermal growth factor receptors
[20,21] are being developed for ovarian cancer therapy.
Clinical trials evaluating such agents, alone and in combi-
nation with chemotherapy, are urgently needed. It is no
doubt likely that more than one subset of cell adhesion
molecules will play a role in overall efficiency of second-
ary tumor establishment, but our studies show that a
paracrine IL-1b/b1 integrin axis may play an important
role in the early events of ovarian tumor cell metastasis
and deserves further investigation in this context.
List of abbreviations
OC: ovarian cancer; IL: interleukin; FBS: fetal bovine serum; U: units; RT-PCR:
reverse-transcriptase polymerase chain reaction; GFP: green fluorescent
protein; MCs: mesothelial cells.
Acknowledgements
Financial support: Grant-in-Aid for Scientific Research; Japan Society for the
Promotion of Science
Author details
1Department of Obstetrics and Gynecology, Fukushima Medical University
School of Medicine, Fukushima, Japan.
2Department of Gynecology, Tsuboi
Cancer Center Hospital, Koriyama, Japan.
3Department of Pathology,
Fukushima Medical University School of Medicine, Fukushima, Japan.
4Cancer
Research Institute, M. D. Anderson Cancer Center Orlando, Orlando, FL, USA.
Authors’ contributions
TW participated in all aspects of the study, from design to clinical and
laboratory performance, and manuscript writing. TH established MFOC3 and
participated in the cDNA microarray analyses. TS aided in conception,
design, and experimentation, particularly immunohistochemistry. SS
performed cell culture and adhesion assays. HM performed cell culture and
immunoassays. SG participated in design, data analysis and drafting of the
manuscript. YM, HY and KF participated in design and analysis of clinical
data. All authors have read and approved the manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 21 December 2011 Accepted: 1 February 2012
Published: 1 February 2012
References
1. Cannistra SA: Cancer of the ovary. N Engl J Med 2004, 351:2519-2529.
2. Cooper A, DePriest P: Surgical management of women with ovarian
cancer. Semin Oncol 2007, 34:226-233.
3. Engel J, Eckel R, Schubert-Fritschle G, Kerr J, Kuhn W, Diebold J, Kimmig R,
Rehbock J, Holzel D: Moderate progress for ovarian cancer in the last 20
years: prolongation of survival, but no improvement in the cure rate. Eur
J Cancer 2002, 38:2435-2445.
4. Niedbala MJ, Crickard K, Bernacki RJ: Interactions of human ovarian tumor
cells with human mesothelial cells grown on extracellular matrix. An in
vitro model system for studying tumor cell adhesion and invasion. Exp
Cell Res 1985, 160:499-513.
5. Lessan K, Aguiar DJ, Oegema T, Siebenson L, Skubitz AP: CD44 and beta1
integrin mediate ovarian carcinoma cell adhesion to peritoneal
mesothelial cells. Am J Pathol 1999, 154:1525-1537.
6. Burleson KM, Hansen LK, Skubitz AP: Ovarian carcinoma spheroids
disaggregate on type I collagen and invade live human mesothelial cell
monolayers. Clin Exp Metastasis 2004, 21:685-697.
7. Strobel T, Cannistra SA: Beta1-integrins partly mediate binding of ovarian
cancer cells to peritoneal mesothelium in vitro. Gynecol Oncol 1999,
73:362-367.
8. Sawada K, Radjabi AR, Shinomiya N, Kistner E, Kenny H, Becker AR,
Turkyilmaz MA, Salgia R, Yamada SD, Vande Woude GF, et al: c-Met
overexpression is a prognostic factor in ovarian cancer and an effective
target for inhibition of peritoneal dissemination and invasion. Cancer Res
2007, 67:1670-1679.
9. Fukuda T, Oyamada H, Isshiki T, Maeda M, Kusakabe T, Hozumi A,
Yamaguchi T, Igarashi T, Hasegawa H, Seidoh T, Suzuki T: Distribution and
variable expression of secretory pathway protein reticulocalbin in
normal human organs and non-neoplastic pathological conditions. J
Histochem Cytochem 2007, 55:335-345.
10. McAlindon ME, Hawkey CJ, Mahida YR: Expression of interleukin 1 beta
and interleukin 1 beta converting enzyme by intestinal macrophages in
health and inflammatory bowel disease. Gut 1998, 42:214-219.
11. Shchors K, Shchors E, Rostker F, Lawlor ER, Brown-Swigart L, Evan GI: The
Myc-dependent angiogenic switch in tumors is mediated by interleukin
1beta. Genes Dev 2006, 20:2527-2538.
12. Bruns CJ, Harbison MT, Kuniyasu H, Eue I, Fidler IJ: In vivo selection and
characterization of metastatic variants from human pancreatic
adenocarcinoma by using orthotopic implantation in nude mice.
Neoplasia 1999, 1:50-62.
13. Pettaway CA, Pathak S, Greene G, Ramirez E, Wilson MR, Killion JJ, Fidler IJ:
Selection of highly metastatic variants of different human prostatic
carcinomas using orthotopic implantation in nude mice. Clin Cancer Res
1996, 2:1627-1636.
14. Stadlmann S, Raffeiner R, Amberger A, Margreiter R, Zeimet AG,
Abendstein B, Moser PL, Mikuz G, Klosterhalfen B, Offner FA: Disruption of
the integrity of human peritoneal mesothelium by interleukin-1beta and
tumor necrosis factor-alpha. Virchows Arch 2003, 443:678-685.
15. Strobel T, Tai YT, Cannistra SA: Binding of ovarian cancer cell to peritoneal
mesothelium in vitro is partly mediated by beta 1 integrins. Proceedings
of the American Association for Cancer Research 1998, 39:497.
Watanabe et al. Journal of Ovarian Research 2012, 5:7
http://www.ovarianresearch.com/content/5/1/7
Page 12 of 1316. Catterall JB, Gardner MJ, Jones LM, Thompson GA, Turner GA: A precise,
rapid and sensitive in vitro assay to measure the adhesion of ovarian
tumour cells to peritoneal mesothelial cells. Cancer Lett 1994, 87:199-203.
17. Jones LM, Gardner MJ, Catterall JB, Turner GA: Hyaluronic acid secreted by
mesothelial cells: a natural barrier to ovarian cancer cell adhesion. Clin
Exp Metastasis 1995, 13:373-380.
18. Dejana E, Bertocchi F, Bortolami MC, Regonesi A, Tonta A, Breviario F,
Giavazzi R: Interleukin 1 promotes tumor cell adhesion to cultured
human endothelial cells. J Clin Invest 1988, 82:1466-1470.
19. Lee KH, Lawley TJ, Xu YL, Swerlick RA: VCAM-1-, ELAM-1-, and ICAM-1-
independent adhesion of melanoma cells to cultured human dermal
microvascular endothelial cells. J Invest Dermatol 1992, 98:79-85.
20. Hussain MM, Kotz H, Minasian L, Premkumar A, Sarosy G, Reed E, Zhai S,
Steinberg SM, Raggio M, Oliver VK, et al: Phase II trial of
carboxyamidotriazole in patients with relapsed epithelial ovarian cancer.
J Clin Oncol 2003, 21:4356-4363.
21. Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowitz IR:
Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab,
in patients with recurrent or refractory ovarian or primary peritoneal
carcinoma with overexpression of HER2: a phase II trial of the
Gynecologic Oncology Group. J Clin Oncol 2003, 21:283-290.
22. Byzova TV, Kim W, Midura RJ, Plow EF: Activation of integrin alpha(V)beta
(3) regulates cell adhesion and migration to bone sialoprotein. Exp Cell
Res 2000, 254:299-308.
23. Margetts PJ, Kolb M, Yu L, Hoff CM, Holmes CJ, Anthony DC, Gauldie J:
Inflammatory cytokines, angiogenesis, and fibrosis in the rat
peritoneum. Am J Pathol 2002, 160:2285-2294.
24. Mandl-Weber S, Cohen CD, Haslinger B, Kretzler M, Sitter T: Vascular
endothelial growth factor production and regulation in human
peritoneal mesothelial cells. Kidney Int 2002, 61:570-578.
25. Zeimet AG, Widschwendter M, Knabbe C, Fuchs D, Herold M, Muller-
Holzner E, Daxenbichler G, Offner FA, Dapunt O, Marth C: Ascitic
interleukin-12 is an independent prognostic factor in ovarian cancer. J
Clin Oncol 1998, 16:1861-1868.
26. Holmdahl L, Ivarsson ML: The role of cytokines, coagulation, and
fibrinolysis in peritoneal tissue repair. Eur J Surg 1999, 165:1012-1019.
27. Nagy JA: Peritoneal membrane morphology and function. Kidney Int
Suppl 1996, 56:S2-11.
28. Nagy JA, Morgan ES, Herzberg KT, Manseau EJ, Dvorak AM, Dvorak HF:
Pathogenesis of ascites tumor growth: angiogenesis, vascular
remodeling, and stroma formation in the peritoneal lining. Cancer Res
1995, 55:376-385.
29. Volz J, Volz-Koster S, Kanis S, Klee D, Ahlert C, Melchert F: Modulation of
tumor-induced lethality after pneumoperitoneum in a mouse model.
Cancer 2000, 89:262-266.
30. van Rossen ME, Hofland LJ, van den Tol MP, van Koetsveld PM, Jeekel J,
Marquet RL, van Eijck CH: Effect of inflammatory cytokines and growth
factors on tumour cell adhesion to the peritoneum. J Pathol 2001,
193:530-537.
31. van Grevenstein WM, Hofland LJ, van Rossen ME, van Koetsveld PM,
Jeekel J, van Eijck CH: Inflammatory cytokines stimulate the adhesion of
colon carcinoma cells to mesothelial monolayers. Dig Dis Sci 2007,
52:2775-2783.
32. Malik ST, East N, Boraschi D, Balkwill FR: Effects of intraperitoneal
recombinant interleukin-1 beta in intraperitoneal human ovarian cancer
xenograft models: comparison with the effects of tumour necrosis
factor. Br J Cancer 1992, 65:661-666.
33. Singh H, Sachan R, Goel H, Mittal B: Genetic variants of interleukin-1RN
and interleukin-1beta genes and risk of cervical cancer. BJOG 2008,
115:633-638.
34. Yang Y, Luo C, Feng R, Bi S: The TNF-alpha, IL-1B and IL-10
polymorphisms and risk for hepatocellular carcinoma: a meta-analysis. J
Cancer Res Clin Oncol 2011, 137:947-952.
doi:10.1186/1757-2215-5-7
Cite this article as: Watanabe et al.: Production of IL1-beta by ovarian
cancer cells induces mesothelial cell beta1-integrin expression
facilitating peritoneal dissemination. Journal of Ovarian Research 2012 5:7.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Watanabe et al. Journal of Ovarian Research 2012, 5:7
http://www.ovarianresearch.com/content/5/1/7
Page 13 of 13